Is Bicycle Therapeutics Ltd (BCYC) overvalued? · rev $35.3M
Bicycle Therapeutics Ltd (BCYC) is a biotechnology company listed on US.
This page asks whether Bicycle Therapeutics Ltd (BCYC) looks expensive on cached numbers — not a short thesis.
Latest reported BCYC revenue for 2024-12-31 was $35.3M. Net income was -$169.0M. Revenue was up 30.8% from 2023-12-31 to 2024-12-31. BCYC currently screens at market cap $554.0M.
BCYC currently screens at market cap $554.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BCYC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BCYC stock page for the full model, not this heading.
Not investment advice.